188 related articles for article (PubMed ID: 36849307)
1. Distinctive Attributes of Indian Patients With Classical BCR::ABL1 Negative Myeloproliferative Neoplasms: Unified Clinical and Laboratory Data.
Singh S; Singh J; Mehta A; Sharma R; Joshi K; Jain K; Paul D; Oberoi G; Jindal N; Dhillon B; Narang V
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):360-369.e1. PubMed ID: 36849307
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
[TBL] [Abstract][Full Text] [Related]
3. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
4. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
5. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
6. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
7. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
8. [The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].
Lyu XD; Li YW; Guo Z; Xin YP; Hu JY; Fan RH; Song YP
Zhonghua Nei Ke Za Zhi; 2020 Jan; 59(1):35-39. PubMed ID: 31887834
[No Abstract] [Full Text] [Related]
9. JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms.
Giraldo-Rincón AI; Naranjo Molina S; Gomez-Lopera N; Aguirre Acevedo D; Ucroz Benavidez A; Gálvez Cárdenas K; Cuellar Ambrosí F; Torres JD; Ospina S; Palacio K; Gaviria Jaramillo L; Muñeton CM; Vasquez Palacio G
Colomb Med (Cali); 2023; 54(3):e2035353. PubMed ID: 38111518
[TBL] [Abstract][Full Text] [Related]
10. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Labastida-Mercado N; Galindo-Becerra S; Garcés-Eisele J; Colunga-Pedraza P; Guzman-Olvera V; Reyes-Nuñez V; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Hematol Oncol Stem Cell Ther; 2015 Mar; 8(1):16-21. PubMed ID: 25637689
[TBL] [Abstract][Full Text] [Related]
11. The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.
Lin Y; Liu E; Sun Q; Ma J; Li Q; Cao Z; Wang J; Jia Y; Zhang H; Song Z; Ai X; Shi L; Feng X; Li C; Wang J; Ru K
Am J Clin Pathol; 2015 Jul; 144(1):165-71. PubMed ID: 26071474
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Rumi E; Cazzola M
Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
[TBL] [Abstract][Full Text] [Related]
13. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018.
Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA
BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359
[TBL] [Abstract][Full Text] [Related]
14. Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
Helbig G
Med Oncol; 2018 Aug; 35(9):119. PubMed ID: 30074114
[TBL] [Abstract][Full Text] [Related]
15. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetic evaluation of myeloproliferative neoplasms.
Azzato EM; Bagg A
Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
[TBL] [Abstract][Full Text] [Related]
17. Myeloproliferative Neoplasms: A Contemporary Review.
Tefferi A; Pardanani A
JAMA Oncol; 2015 Apr; 1(1):97-105. PubMed ID: 26182311
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
Tefferi A; Guglielmelli P; Larson DR; Finke C; Wassie EA; Pieri L; Gangat N; Fjerza R; Belachew AA; Lasho TL; Ketterling RP; Hanson CA; Rambaldi A; Finazzi G; Thiele J; Barbui T; Pardanani A; Vannucchi AM
Blood; 2014 Oct; 124(16):2507-13; quiz 2615. PubMed ID: 25037629
[TBL] [Abstract][Full Text] [Related]
19. Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of
Abbou N; Piazzola P; Gabert J; Ernest V; Arcani R; Couderc AL; Tichadou A; Roche P; Farnault L; Colle J; Ouafik L; Morange P; Costello R; Venton G
Cells; 2022 Dec; 12(1):. PubMed ID: 36611899
[No Abstract] [Full Text] [Related]
20. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
